Trial reportJournal of neurology, neurosurgery, and psychiatry2014
Time to 12-month remission and treatment failure for generalised and unclassified epilepsy.
Trial report in Journal of neurology, neurosurgery, and psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure.The Cochrane database of systematic reviews · 2021Pooled it
- Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure.The Cochrane database of systematic reviews · 2016Pooled it
- Identification of patients who will not achieve seizure remission within 5 years on AEDs.Neurology · 2018Trial
- Breakthrough seizures-Further analysis of the Standard versus New Antiepileptic Drugs (SANAD) study.PloS one · 2017Trial
- Treatment outcome after failure of a first antiepileptic drug.Neurology · 2014Trial
- Guide to evaluating performance of prediction models for recurrent clinical events.Diagnostic and prognostic research · 2025Article
- The Role of Pharmacists' Interventions in Increasing Medication Adherence of Patients With Epilepsy: A Scoping Review.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2024Article
- Effect of Mobile Health Applications on Improving Self-Management Knowledge and Seizure Control in Epilepsy Patients: A Scoping Review.Healthcare informatics research · 2024Article
- Modelling seizure rates rather than time to an event within clinical trials of antiepileptic drugs.BMC medical research methodology · 2020Article
- Article
- Dynamic longitudinal discriminant analysis using multiple longitudinal markers of different types.Statistical methods in medical research · 2018Article
- Clinical risk factors associated with anti-epileptic drug responsiveness in canine epilepsy.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesTo develop prognostic models for time to 12-month remission and time to treatment failure after initiating antiepileptic drug monotherapy for generalised and unclassified epilepsy.
methodsWe analysed data from the Standard and New Antiepileptic Drug (arm B) study, a randomised trial that compared initiating treatment with lamotrigine, topiramate and valproate in patients diagnosed with generalised or unclassified epilepsy. Multivariable regression modelling was used to investigate how clinical factors affect the probability of achieving 12-month remission and treatment failure.
resultsSignificant factors in the multivariable model for time to 12-month remission were having a relative with epilepsy, neurological insult, total number of tonic-clonic seizures before randomisation, seizure type and treatment. Significant factors in the multivariable model for time to treatment failure were treatment history (antiepileptic drug treatment prior to randomisation), EEG result, seizure type and treatment.
conclusionsThe models described within this paper can be used to identify patients most likely to achieve 12-month remission and most likely to have treatment failure, aiding individual patient risk stratification and the design and analysis of future epilepsy trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.